Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Jens Jordan, Arne Astrup, Stefan Engeli, Krzysztof Narkiewicz, Wesley W Day, Nick Finer

Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
OriginalsprogEngelsk
TidsskriftJournal of Hypertension
Vol/bind32
Udgave nummer6
Sider (fra-til)1178-1188
Antal sider11
ISSN0263-6352
DOI
StatusUdgivet - 2014

Bibliografisk note

CURIS 2014 NEXS 100

ID: 105856192